Neurological disorders Archives

News and Trends 26 Sep 2016

UPDATE: AC Immune rakes in €52.5M IPO for assault on Alzheimers

It’s not the $700M headlines imply, but AC Immune is winding up to make a splashy IPO of €52.5M to establish itself in the Alzheimer’s Disease space. You might have read about AC Immune‘s ‘$700M IPO’ and thought, “gee, that can’t be right – that sum is roughly half of the total from all European companies […]

September 26, 2016 - 2 minutesmins - By Evelyn Warner

multiple sclerosis by decade3d anatomy online FI

News and Trends 15 Sep 2016

Roche’s New Antibody is besting the best MS Drug

Roche is poised to blow away the competition for the new multiple sclerosis drug with its leading candidate, Ocrevus (ocrelizumab). Phase III data shows it outperforming Merck’s Rebif, the standard therapy for MS. Competition for a new MS drug has been stiff, but new promising data from the Phase III trial of Ocrevus (ocrelizumab) suggests […]

September 15, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 14 Sep 2016

This French Startup brings Gene Therapy to Neurodegenerative Diseases

There were many exciting developments for CNS disease treatments last year, and now a French biotech is winding up to add gene therapy to the mix. BrainVectis just closed its Series A round with €1M. Paris-based BrainVectis wants to apply some of the hottest technology in biotech, gene therapy, to neurodegenerative disease, and it just […]

September 14, 2016 - 3 minutesmins - By Evelyn Warner

News and Trends 9 Sep 2016

Novel biopharma’s therapy for Traumatic Brain Injury heads to Phase III

A German biotech has surfaced with a promising new drug for traumatic brain injury: vasopharm’s Nitrous Oxide Synthase inhibitor is starting Phase III. In news from the novel and obscure, someone has taken an interest in Nitrous Oxide Synthase (NOS). That someone is vasopharm GmbH, a small German biopharmaceutical company interested in cerebrovascular diseases. The company has […]

September 9, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 30 Aug 2016

New non-amphetaminic ADHD drug ‘speeds’ into Phase II

ADHD is believed to affect up to 7% of people worldwide, but some common therapies bear a shocking resemblance to Speed. A new drug from NLS, Mazindol, just entered Phase II and could set a new non-amphetaminic standard. The treatment of Attention Deficit Hyperactive Disorder (ADHD) is hotly debated in the US, were almost 10% […]

August 30, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 26 Aug 2016

US Money Magnet get hands on UK Bispecific Antibodies for Neurodegenerative Disease

F-star’s “plug-and-play” technology can turn any existing antibody into a full-size bispecific antibody. Denali has recognized its potential use for drug delivery to the CNS and inked a deal with the UK-based company for almost €1B. Denali (US) and F-Star (UK) have struck a deal to develop F-star’s Modular Antibody Technology™ for the generation of […]

August 26, 2016 - 2 minutesmins - By Evelyn Warner

sleep homeostasis sandman channel oxford cncb

News and Trends 8 Aug 2016

The Brain’s Sleep Switch was just discovered, zZz …

Researchers from the University of Oxford have discovered how certain neurons control when we go to sleep. The biology behind it involves an ion channel that reacts to the ‘happy chemical’ dopamine, changing places in the neurons. Sleep is essential to health, with the Center for Disease Control even calling insufficient sleep a public health […]

August 8, 2016 - 3 minutesmins - By Denise Neves Gameiro

galvani bioelectronics electroceuticals gsk verily google

News and Trends 2 Aug 2016

Google and GSK invest €630M to create a new Bioelectronics Champion

GSK and Verily Life Sciences are creating a new company together, Galvani Bioelectronics. Along with €630M in investment, it’ll inherit intellectual property to pioneer a new class of therapies – bioelectronic medicines. GSK is one of the big Pharma based in Europe and has had a strong presence in many hype fields of medical Biotech. Examples are […]

August 2, 2016 - 3 minutesmins - By Denise Neves Gameiro

taurx tau protein tangles biotech alzheimers

News and Trends 28 Jul 2016

World first Drug to ‘dissolve’ Tau-tangles in Alzheimer’s has Phase III Results

The much-anticipated results of TauRx’s Phase III trial for Alzheimer’s disease have finally been disclosed. Despite some complicated effects, this could be the first available working therapy for Alzheimer’s patients. According to the WHO, Alzheimer’s disease is the cause of up to 70% of dementia cases, which translates to over 30 million patients worldwide. As the world population ages, Alzheimer’s […]

July 28, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 22 Jul 2016

Oryzon develops Epigenetic Therapies against Cancer and Alzheimer’s

This week we’re exchanging a very warm and welcoming country for another. We are heading to Barcelona, the wonderful capital of Catalunya in Spain, to visit Oryzon, our Biotech of The Week and maybe (just maybe) have a little swim in the Barceloneta beach. City: Barcelona (Spain) Founded: 2000 Employees: 35 Financial Data: €81.50M Market Cap (Bolsa de […]

July 22, 2016 - 2 minutesmins - By Joachim Eeckhout

News and Trends 14 Jul 2016

Sci-fi Spinal Cord Implant could help Paralyzed Patients walk again

Getting up from a wheelchair is a shared dream of paralyzed people all across the world. A dream that might soon become true thanks to a new skin-like implant that directly stimulates the patients’ spinal cord through electric pulses. The sci-fi technology developed by researchers at École Polytechnique Fédérale of Lausanne (EPFL) in Switzerland has […]

July 14, 2016 - 2 minutesmins - By Lourdes Riquelme

pharnext marie tooth disease IPO pharnext

News and Trends 14 Jul 2016

French Biotech that makes Drugs faster and cheaper IPO’s for €31M

Pharnext has successfully completed its IPO on the Euronext Paris exchange, allowing it to move forward with Phase II and III trials for Neurological diseases that include Alzheimer’s. Based in Paris, Pharnext is developing new therapies for neurological conditions, including rare diseases such as Charcot-Marie-Tooth Disease. New partners to join this biotech in the €31M IPO include Galapagos […]

July 14, 2016 - 2 minutesmins - By Dani Bancroft

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Neurological disorders

UPDATE: AC Immune rakes in €52.5M IPO for assault on Alzheimers

Roche’s New Antibody is besting the best MS Drug

This French Startup brings Gene Therapy to Neurodegenerative Diseases

Novel biopharma’s therapy for Traumatic Brain Injury heads to Phase III

New non-amphetaminic ADHD drug ‘speeds’ into Phase II

US Money Magnet get hands on UK Bispecific Antibodies for Neurodegenerative Disease

The Brain’s Sleep Switch was just discovered, zZz …

Google and GSK invest €630M to create a new Bioelectronics Champion

World first Drug to ‘dissolve’ Tau-tangles in Alzheimer’s has Phase III Results

Oryzon develops Epigenetic Therapies against Cancer and Alzheimer’s

Sci-fi Spinal Cord Implant could help Paralyzed Patients walk again

French Biotech that makes Drugs faster and cheaper IPO’s for €31M

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!